A two-phase study evaluating the relationship between Thimerosal-containing vaccine administration and the risk for an autism spectrum disorder diagnosis in the United States
Autism spectrum disorder (ASD) is defined by standardized criteria of qualitative impairments in social interaction, qualitative impairments in communication, and restricted and stereotyped patterns of behavior, interests, and activities. A significant number of children diagnosed with ASD suffer a loss of previously-acquired skills, which is suggestive of neurodegeneration or a type of progressive encephalopathy with an etiological pathogenic basis occurring after birth. To date, the etiology of ASD remains under debate, however, many studies suggest toxicity, especially from mercury (Hg), in individuals diagnosed with an ASD. The present study evaluated concerns about the toxic effects of organic-Hg exposure from Thimerosal (49.55% Hg by weight) in childhood vaccines by conducting a two-phased (hypothesis generating/hypothesis testing) study with documented exposure to varying levels of Thimerosal from vaccinations.
A hypothesis generating cohort study was undertaken to evaluate the relationship between exposure to organic-Hg from a Thimerosal-containing Diphtheria-Tetanus-acellular-Pertussis (DTaP) vaccine in comparison to a Thimerosal-free DTaP vaccine administered, from 1998 through 2000, for the risk of ASD as reported in the Vaccine Adverse Event Reporting System (VAERS) database (phase I). A hypothesis testing case–control study was undertaken to evaluate the relationship between organic-Hg exposure from Thimerosal-containing hepatitis B vaccines administered at specific intervals in the first six months of life among cases diagnosed with an ASD and controls born between 1991 through 1999 in the Vaccine Safety Datalink (VSD) database (phase II).
In phase I, it was observed that there was a significantly increased risk ratio for the incidence of ASD reported following the Thimerosal-containing DTaP vaccine in comparison to the Thimerosal-free DTaP vaccine. In phase II, it was observed that cases diagnosed with an ASD were significantly more likely than controls to receive increased organic-Hg from Thimerosal-containing hepatitis B vaccine administered within the first, second, and sixth month of life.
Routine childhood vaccination is an important public health tool to reduce the morbidity and mortality associated with infectious diseases, but the present study provides new epidemiological evidence supporting an association between increasing organic-Hg exposure from Thimerosal-containing childhood vaccines and the subsequent risk of an ASD diagnosis.
- Boyle CA, Boulet S, Schieve LA, Cohen RA, Blumberg SJ, Yeargin-Allsopp M, Visser S, Kogan MD: Trends in the prevalence of developmental disabilities in US children, 1997–2008. Pediatrics 2011, 127:1034–1042. CrossRef
- Autism and Developmental Disabilities Monitoring Network Surveillance Year 2008 Principal Investigators; Centers for Disease Control and Prevention: Prevalence of autism spectrum disorders-Autism and Developmental Disabilities Monitoring Network, 14 sites, United States, 2008. MMWR Surveill Summ 2012, 61:1–19.
- Geier DA, Kern JK, Geier MR: A comparison of the Autism Treatment Evaluation Checklist (ATEC) and the Childhood Autism Rating Scale (CARS) for the quantitative evaluation of autism. J Ment Health Res Intellect Disabil 2013, 6:255–267. CrossRef
- Geier DA, Kern JK, Geier MR: A prospective cross-sectional cohort assessment of health, physical, and behavioral problems in autism spectrum disorders. Maedica (Buchar) 2012, 7:193–200.
- Kern JK, Geier DA, Sykes LK, Geier MR: Evidence of neurodegeneration in autism spectrum disorder. Transl Neurodegener 2013, 2:17. CrossRef
- Desoto MC, Hitlan RT: Sorting out the spinning of autism: heavy metals and the question of incidence. Acta Neurobiol Exp (Wars) 2010, 70:165–176.
- Kern JK, Geier DA, Audhya T, King PG, Sykes LK, Geier MR: Evidence of parallels between mercury intoxication and the brain pathology in autism. Acta Neurobiol Exp (Wars) 2012, 72:113–153.
- Geier DA, King PG, Sykes LK, Geier MR: A comprehensive review of mercury provoked autism. Indian J Med Res 2008, 128:383–411.
- Kern JK, Haley BE, Geier DA, Sykes LK, King PG, Geier MR: Thimerosal exposure and the role of sulfation chemistry and thiol availability in autism. Int J Environ Res Public Health 2013, 10:3771–3800. CrossRef
- Ball LK, Ball R, Pratt RD: An assessment of Thimerosal use in childhood vaccines. Pediatrics 2001, 107:1147–1154. CrossRef
- Singleton JA, Lloyd JC, Mootrey GT, Salive ME, Chen RT: An overview of the vaccine adverse event reporting system (VAERS) as a surveillance system. VAERS Working Group. Vaccine 1999, 17:2908–2917.
- Geier DA, Geier MR: A review of the vaccine adverse event reporting system database. Expert Opin Pharmacother 2004, 5:691–698. CrossRef
- Chen RT, DeStefano F, Davis RL, Jackson LA, Thompson RS, Mullooly JP, Black SB, Shinefield HR, Vadheim CM, Ward JI, Marcy SM: The vaccine safety datalink: immunization research in health maintenance organizations in the USA. Bull World Health Organ 2000, 78:186–194.
- Chen RT, Glasser JW, Rhodes PH, Davis RL, Barlow WE, Thompson RS, Mullooly JP, Black SB, Shinefield HR, Vadheim CM, March SM, Ward JI, Wise RP, Wassilak SG, Hadler SC: Vaccine Safety Datalink project: a new tool for improving vaccine safety monitoring in the United States. The Vaccine Safety Datalink Team. Pediatrics 1997, 99:765–773.
- Wassilak SG, Glasser JW, Chen RT, Hadler SC: Utility of large-linked databases in vaccine safety, particularly in distinguishing independent and synergistic effects. The Vaccine Safety Datalink Investigators. Ann N Y Acad Sci 1995, 754:377–382. CrossRef
- Ellenberg SS, Braun MM: Monitoring the safety of vaccines: assessing the risks. Drug Saf 2002, 25:145–152. CrossRef
- Varricchio F, Iskander J, Destefano F, Ball R, Pless R, Braun MM, Chen RT: Understanding vaccine safety information from the vaccine adverse event reporting system. Pediatr Infect Dis J 2004, 23:287–294. CrossRef
- Iskander J, Pool V, Zhou W, English-Bullard R: VAERS Team. Data mining in the US using the vaccine adverse event reporting system. Drug Saf 2006, 29:375–384. CrossRef
- Pertussis vaccination: use of acellular pertussis vaccines among infants and young children. Recommendations of the Advisory Committee on Immunization Practices MMWR Recomm Rep 1997, 46:1–25.
- Hepatitis B virus: a comprehensive strategy for eliminating transmission in the United States through universal childhood vaccination. Recommendations of the Immunization Practices Advisory Committee (ACIP) MMWR Recomm Rep 1991, 40:1–25.
- Clarkson TW, Nordberg GF, Sager PR: Reproductive and developmental toxicity of metals. Scan J Work Environ Health 1985, 11:145–154. CrossRef
- Burbacher TM, Shen DD, Liberato N, Grant KS, Cernichiari E, Clarkson T: Comparison of blood and brain mercury levels in infant monkeys exposed to methylmercury or vaccines containing Thimerosal. Environ Health Perpsect 2005, 113:1015–1021. CrossRef
- Rodrigues JL, JM S i, Batista BL, Souza SS, Barbosa F Jr: Identification and distribution of mercury species in rat tissues following administration of Thimerosal or methylmercury. Arch Toxicol 2010, 84:891–896. CrossRef
- Zimmermann LT, Santos DB, Naime AA, Leal RB, Dorea JG, Barbosa F Jr, Aschner M, Rocha JB, Farina M: Comparative study on methyl- and ethylmercury-induced toxicity in C6 glioma cells and the potential role of LAT-1 in mediating mercurial-thiol complexes uptake. Neurotoxicology 2013, 38:1–8. CrossRef
- Geier DA, King PG, Geier MR: Mitochondrial dysfunction, impaired oxidative-reduction activity, degeneration, and death in human neuronal and fetal cells induced by low-level exposure to Thimerosal and other metal compounds. Toxicol Environ Chem 2009, 91:735–749. CrossRef
- Young HA, Geier DA, Geier MR: Thimerosal exposure in infants and neurodevelopmental disorders: an assessment of computerized medical records in the Vaccine Safety Datalink. J Neurol Sci 2008, 271:110–118. CrossRef
- Gallagher CM, Goodman MS: Hepatitis B vaccination of male neonates and autism diagnosis, NHIS 1997–2002. J Toxicol Environ Health A 2010, 73:1665–1677. CrossRef
- Geier DA, Geier MR: A meta-analysis epidemiological assessment of neurodevelopmental disorders following vaccines administered from 1994 through 2000 in the United States. Neuro Endocrinol Lett 2006, 27:401–413.
- Hviid A, Stellfeld M, Wohlfahrt J, Melbye M: Association between Thimerosal-containing vaccine and autism. JAMA 2003, 290:1763–1766. CrossRef
- Andrews N, Miller E, Grant A, Stowe J, Osborne V, Taylor B: Thimerosal exposure in infants and developmental disorders: a retrospective cohort study in the United Kingdom does not support a causal association. Pediatrics 2004, 114:584–591. CrossRef
- Verstraeten T, Davis RL, DeStefano F, Lieu TA, Rhodes PH, Black SB, Shinefield H, Chen RT: Vaccine safety datalink team. Safety of thimerosal-containing vaccines: a two-phased study of computerized health maintance organization databases. Pediatrics 2003, 112:1039–1048. CrossRef
- Chen RT, Rosenthal S: An errant critique that misses the mark. Arch Pediatr Adlesc Med 1996, 150:464–465. CrossRef
- A two-phase study evaluating the relationship between Thimerosal-containing vaccine administration and the risk for an autism spectrum disorder diagnosis in the United States
- Open Access
- Available under Open Access This content is freely available online to anyone, anywhere at any time.
- Online Date
- December 2013
- Online ISSN
- BioMed Central
- Additional Links
- Author Affiliations
- 1. The Institute of Chronic Illnesses Inc, 14 Redgate Ct, Silver Spring, MD, USA
- 2. Simpson University, Redding, CA, USA
- 3. University of Texas Southwestern Medical Center at Dallas, Dallas, TX, USA
- 4. CoMeD Inc, Silver Spring, MD, USA